Although DHODH is not known to be mutated or over-expressed in patients with cancer, DHODH inhibitors are able to shrink tumor burden and improve survival by inducting leukemic cells differentiation in preclinical AML models (168). This evidence concerns the gene DHODH and neoplasm.